Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center.
View/ Open
Date
2019-10-14Author
Georgiou, A
Khakoo, S
Edwards, P
Minchom, A
Kouvelakis, K
Kalaitzaki, E
Nobar, N
Calamai, V
Ifijen, M
Husson, O
Watkins, D
Rao, S
Chau, I
Cunningham, D
Starling, N
Type
Journal Article
Metadata
Show full item recordAbstract
The incidence of early onset colorectal cancer (EOCRC) is rapidly increasing, but there remains paucity of outcome data for young CRC patients. We reviewed the characteristics and outcomes of 241 adults, age <50, who were diagnosed with EOCRC between January 2009 and December 2014. Median age was 42, 56% were male, and 7% had hereditary etiology. Seventy percent had left-sided primaries. At diagnosis, 11%, 50%, and 39% had stage II, III, and IV CRC. Of the patients with stage II and III CRC who underwent curative surgery, 60% and 88% had adjuvant chemotherapy, with 5-year relapse free survival of 82% and 74% respectively. Of the 123 patients with metastatic (m) EOCRC, 93%, 63%, 33%, and 12% had 1st, 2nd, 3rd, and 4th line systemic anticancer therapy (SACT) respectively. For first line SACT, 99% had doublet chemotherapy, with bevacizumab or an anti-EGFR antibody in 57%. Median overall survival (mOS) of mEOCRC patients was 20.1 months (95% C.I: 15.9-23.2). Younger age and signet cells were associated with shorter mOS, whereas more lines of SACT and curative metastasectomy with longer mOS. Metastatic EOCRC patients had poorer outcomes than expected, despite optimal multimodality treatment. This suggests an aggressive disease biology that warrants further research and therapy development.
Collections
Research team
Clinical and Translational Sarcoma
Clinical Pharmacology – Adaptive Therapy
Gastrointestinal Cancers Clinical Trials
Medicine (RMH Smith Cunningham)
Language
eng
Date accepted
2019-10-10
License start date
2019-10-14
Citation
Cancers, 2019, 11 (10)
Publisher
MDPI